Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

Editor’s note: A breaking-news bulletin linked to this story inaccurately characterized the number of years that have passed since Sangamo Therapeutics shares lost as much in a single session.

In this article, we are going to take a look at where Sangamo Therapeutics Inc. (NASDAQ:SGMO) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation ...

HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research note published on Monday,Benzinga reports. They currently have a $10.00 price ...

9 analysts have shared their evaluations of Sangamo Therapeutics (NASDAQ:SGMO) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a ...

Truist analyst Nicole Germino lowered the firm’s price target on Sangamo (SGMO) to $5 from $7 and keeps a Buy rating on the shares. The firm ...

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, ...

Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.09, accompanied by a high estimate of $10.00 and a low estimate of $2.00. Surpassing ...